<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - TIROFIBAN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>TIROFIBAN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">In combination with unfractionated heparin, aspirin, and clopidogrel for prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction (NSTEMI) and with last episode of chest pain within 12 hours (with angiopraphy planned for 4&#8211;48 hours after diagnosis (initiated under specialist supervision)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 400 nanograms/kg/minute for 30 minutes, then 100 nanograms/kg/minute for at least 48 hours (continue during and for 12&#8211;24 hours after percutaneous coronary intervention), maximum duration of treatment 108 hours.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">In combination with unfractionated heparin, aspirin, and clopidogrel for prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction (NSTEMI) and with last episode of chest pain within 12 hours (within 4 hours of diagnosis) (initiated under specialist supervision)</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                25 micrograms/kg, to be given over 3 minutes at start of percutaneous coronary intervention, then (by intravenous infusion) 150 nanograms/kg/minute for 12&#8211;24 hours, maximum duration of treatment 48 hours.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">In combination with unfractionated heparin, aspirin, and clopidogrel for reduction of major cardiovascular events in patients with ST-segment elevation myocardial infarction (STEMI) intended for primary percutaneous coronary intervention (PCI) (initiated under specialist supervision)</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                25 micrograms/kg, to be given over 3 minutes at start of percutaneous coronary intervention, then (by intravenous infusion) 150 nanograms/kg/minute for 12&#8211;24 hours, maximum duration of treatment 48 hours.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises use only if potential benefit outweighs risk&#8212;no information available.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Caution in mild to moderate liver disease.</p><p>Avoid in severe liver disease&#8212;increased risk of bleeding.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Use half normal dose if eGFR less than 30&#8239;mL/minute/ 1.73&#8239;m<sup>2</sup>.</p>
            </section>
        
            <section class="generalInformation">
              <p>Increased risk of bleeding.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Abnormal bleeding within 30 days</li>
            <li>history of aneurysm</li>
            <li>history of arteriovenous malformation</li>
            <li>history of haemorrhagic stroke</li>
            <li>history of intracranial disease</li>
            <li>history of neoplasm</li>
            <li>increased INR</li>
            <li>increased prothrombin time</li>
            <li>severe hypertension</li>
            <li>stroke within 30 days</li>
            <li>thrombocytopenia</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Bleeding manifestations, fever, headache, nausea, reversible thrombocytopenia,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>For <i>intravenous infusion</i> (<i>Aggrastat</i>
            <tm tmtype="reg"/>), give continuously in Glucose 5% or Sodium chloride 0.9%. Withdraw 50&#8239;mL infusion fluid from 250&#8239;mL bag and replace with 50&#8239;mL tirofiban concentrate (250&#8239;micrograms/mL) to give a final concentration of 50&#8239;micrograms/mL.</p>
            </section>
      </section>




      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Active peptic ulcer (within 3 months)
          </li>
          <li>
            acute pericarditis
          </li>
          <li>
            anaemia
          </li>
          <li>
            aortic dissection
          </li>
          <li>
            cardiogenic shock
          </li>
          <li>
            discontinue if intra-aortic balloon pump necessary
          </li>
          <li>
            discontinue if thrombolytic therapy necessary
          </li>
          <li>
            discontinue immediately if serious or uncontrollable bleeding occurs
          </li>
          <li>
            discontiue if emergency cardiac surgery necessary
          </li>
          <li>
            elderly
          </li>
          <li>
            faecal occult blood
          </li>
          <li>
            haematuria
          </li>
          <li>
            haemorrhagic retinopathy
          </li>
          <li>
            low body-weight
          </li>
          <li>
            major surgery within 3 months (avoid if within 6 weeks)
          </li>
          <li>
            organ biopsy or lithotripsy within last 2 weeks
          </li>
          <li>
            puncture of non-compressible vessel within 24 hours
          </li>
          <li>
            risk of bleeding (within 3 months)
          </li>
          <li>
            severe heart failure
          </li>
          <li>
            severe trauma within 3 months (avoid if within 6 weeks)
          </li>
          <li>
            traumatic or protracted cardiopulmonary resuscitation within last 2 weeks
          </li>
          <li>
            uncontrolled severe hypertension
          </li>
          <li>
            vasculitis
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor platelet count, haemoglobin and haematocrit before treatment, 2&#8211;6 hours after start of treatment and then at least once daily.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of TIROFIBAN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP77073"><a href="../medicinalForm/PHP77073.html" data-target="#PHP77073" data-action="load">Infusion</a></div>
            <div id="PHP77064"><a href="../medicinalForm/PHP77064.html" data-target="#PHP77064" data-action="load">Solution for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
